TABLE 4.

Associations of Secondary Outcomes With Presence of Postnatal CMV Infection and Antiviral Treatment

				CMVPNT vs. NEG		CMVPT vs. NEG
	NEG (n = 50)	CMVPNT (n = 26)	CMVPT (n = 27)	OR (95% CI)	P	OR (95% CI)	P
Bronchopulmonary dysplasia [n (%)]	34 (68)	16 (61.5)	23 (85.2)	0.75 (0.28–2.02)	0.574	2.71 (0.8–9.14)	0.109
Intraventricular hemorrhage 3rd or 4th degree [n (%)]	6 (12)	1 (3.8)	1 (3.7)	0.51 (0.1–2.66)	0.426	0.77 (0.18–3.25)	0.72
Necrotizing enterocolitis [n (%)]	7 (14)	1 (3.8)	1 (3.7)	0.25 (0.03–2.11)	0.201	0.24 (0.03–2.03)	0.189
Periventricular leukomalacia [n (%)]	0 (0)	1 (3.8)	0 (0)	–	0.141a	–	1a
Retinopathy of prematurtiy [n (%)]	15 (30)	12 (46.2)	13 (48.1)	2 (0.75–5.33)	0.166	2.17 (0.82–5.7)	0.117
Sepsis [n (%)]	8 (16)	6 (23.1)	4 (14.8)	1.57 (0.48–5.15)	0.452	0.91 (0.25–3.36)	0.891
Transient evoked otoacoustic emissions
Elicited [n (%)]	28 (68.3)	15 (65.2)	14 (63.6)	0.87 (0.3–2.57)	0.802	0.81 (0.27–2.42)	0.709
Not elicited (unilateral or bilateral) [n (%)]	13 (31.7)	8 (34.8)	8 (36.4)
Me (IQR) weight at follow-up [g]	10,000 (9,700–11,500)	10,500 (8,950–10,700)	10,200 (9,450–11,300)	1 (1–1)	0.468	1 (1–1)	0.942
Me (IQR) height at follow-up [cm]	85 (84–88)	88 (82–89)	87 (82–88)	0.98 (0.83–1.15)	0.778	0.99 (0.86–1.13)	0.833
Me (IQR) head circumference at follow-up [cm]	48 (47–49)	48.3 (47.3–49.5)	46.8 (46–48)	1.16 (0.7–1.9)	0.564	0.75 (0.51–1.09)	0.133
Breathing at follow-up				–	0.191a	–	0.171a
Independently [n (%)]	24 (96)	8 (88.9)	11 (78.6)
Addition of oxygen needed [n (%)]	0 (0)	1 (11.1)	1 (7.1)
Addition of oxygen and mechanical ventilation needed [n (%)]	1 (4)	0 (0)	2 (14.3)

CI, confidence interval; CMV_PNT, CMV positive without antiviral treatment group; CMV_PT, CMV positive on antiviral therapy group; IQR, interquartile range; Me, median; n, number of subjects; NEG, CMV negative group (control group); OR, odds ratio.

^aOdds ratio test.